| Title |
|
|
|
Can positron emission tomography with []-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
| |
| Author |
|
|
|
| |
| Abstract |
|
|
|
| To assess the ability of restaging positron emission tomography (PET) scanning to predict clinical outcome after first-line treatment in patients with Hodgkin's disease, we included 60 patients with histologically proven HD, who underwent whole-body [18F]-fluorodeoxygenase ([18F]-FDG)-PET studies after first-line treatment and with a follow-up of at least 1 year. Persistence or absence of residual disease on PET was related to progression-free survival (PFS) using KaplanMeier survival analysis. After treatment, 55 patients showed a normal [18F]-FDG-PET scan; 50 of 55 remained in complete remission (CR), with a median follow-up of 955 d. Only five patients relapsed (median PFS, 296 d). During follow-up in all five patients, [18F]-FDG-PET was the first tool that became positive for relapse. Persistent abnormal [18F]-FDG uptake was seen in only five patients; all of them relapsed (median PFS, 296 d). In four of five patients, only PET predicted persistent disease. All relapses were proven histologically. Two-year actuarial PFS rate for negative patients was 91% compared with 0% for positive patients. We concluded that [18F]-FDG-PET has an important prognostic role in the post-treatment evaluation of HD patients. | | |
| Language |
|
|
|
English
| |
| Source (journal) |
|
|
|
British journal of haematology. - Oxford | |
| Publication |
|
|
|
Oxford : 2001
| |
| ISSN |
|
|
|
0007-1048
| |
| Volume/pages |
|
|
|
115:2(2001), p. 272-278
| |
| ISI |
|
|
|
000172403300007
| |
| Full text (Publisher's DOI) |
|
|
| | |
| Full text (publisher's version - intranet only) |
|
|
| | |
|